The Novel VEGF Receptor/MET–Targeted Kinase Inhibitor TAS-115 Has Marked In Vivo Antitumor Properties and a Favorable Tolerability Profile

VEGF receptor (VEGFR) signaling plays a key role in tumor angiogenesis. Although some VEGFR signal-targeted drugs have been approved for clinical use, their utility is limited by associated toxicities or resistance to such therapy. To overcome these limitations, we developed TAS-115, a novel VEGFR and hepatocyte growth factor receptor (MET)-targeted kinase inhibitor with an improved safety profile. TAS-115 inhibited the kinase activity of both VEGFR2 and MET and their signal-dependent cell growth as strongly as other known VEGFR or MET inhibitors. On the other hand, kinase selectivity of TAS-115 was more specific than that of sunitinib and TAS-115 produced relatively weak inhibition of growth (GI50 > 10 μmol/L) in VEGFR signal- or MET signal-independent cells. Furthermore, TAS-115 induced less damage in various normal cells than did other VEGFR inhibitors. These data suggest that TAS-115 is extremely selective and specific, at least in vitro. In in vivo studies, TAS-115 completely suppressed the progression of MET-inactivated tumor by blocking angiogenesis without toxicity when given every day for 6 weeks, even at a serum-saturating dose of TAS-115. The marked selectivity of TAS-115 for kinases and targeted cells was associated with improved tolerability and contributed to the ability to sustain treatment without dose reduction or a washout period. Furthermore, TAS-115 induced marked tumor shrinkage and prolonged survival in MET-amplified human cancer–bearing mice. These data suggest that TAS-115 is a unique VEGFR/MET-targeted inhibitor with improved antitumor efficacy and decreased toxicity. Mol Cancer Ther; 12(12); 2685–96. ©2013 AACR.

[1]  A. Carrato,et al.  Fluorouracil, leucovorin, and irinotecan plus either sunitinib or placebo in metastatic colorectal cancer: a randomized, phase III trial. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  D. Ichikawa,et al.  HGF regulates VEGF expression via the c-Met receptor downstream pathways, PI3K/Akt, MAPK and STAT3, in CT26 murine cells. , 2013, International journal of oncology.

[3]  T. Tokuyasu,et al.  Gene Expression Profile Identifies Tyrosine Kinase c-Met as a Targetable Mediator of Antiangiogenic Therapy Resistance , 2013, Clinical Cancer Research.

[4]  B. Esterni,et al.  BAYPAN study: a double-blind phase III randomized trial comparing gemcitabine plus sorafenib and gemcitabine plus placebo in patients with advanced pancreatic cancer. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[5]  W. Birchmeier,et al.  Targeting MET in cancer: rationale and progress , 2012, Nature Reviews Cancer.

[6]  John V Heymach,et al.  Prognostic or predictive plasma cytokines and angiogenic factors for patients treated with pazopanib for metastatic renal-cell cancer: a retrospective analysis of phase 2 and phase 3 trials. , 2012, The Lancet. Oncology.

[7]  J. Christensen,et al.  HGF/c-Met pathway is one of the mediators of sunitinib-induced tumor cell type-dependent metastasis. , 2012, Cancer letters.

[8]  G. Scagliotti,et al.  Sunitinib plus erlotinib versus placebo plus erlotinib in patients with previously treated advanced non-small-cell lung cancer: a phase III trial. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  S. Peters,et al.  MET: a promising anticancer therapeutic target , 2012, Nature Reviews Clinical Oncology.

[10]  A. Secord,et al.  Antiangiogenic Agents in Combination With Chemotherapy for the Treatment of Epithelial Ovarian Cancer , 2012, International Journal of Gynecologic Cancer.

[11]  R. Greil,et al.  First-line treatment of advanced breast cancer with sunitinib in combination with docetaxel versus docetaxel alone: results of a prospective, randomized phase III study. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  S. Oudard,et al.  Antiangiogenic therapy for advanced renal cell carcinoma: Management of treatment-related toxicities , 2012, Investigational New Drugs.

[13]  R. Rosell,et al.  Combined VEGF-A and VEGFR-2 concentrations in plasma: diagnostic and prognostic implications in patients with advanced NSCLC. , 2011, Lung cancer.

[14]  R. Jeraj,et al.  Pharmacodynamic Study Using FLT PET/CT in Patients with Renal Cell Cancer and Other Solid Malignancies Treated with Sunitinib Malate , 2011, Clinical Cancer Research.

[15]  H. Rugo,et al.  Randomized, placebo-controlled, double-blind, phase II study of axitinib plus docetaxel versus docetaxel plus placebo in patients with metastatic breast cancer. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  Joon-Oh Park,et al.  Impact of MET amplification on gastric cancer: possible roles as a novel prognostic marker and a potential therapeutic target. , 2011, Oncology reports.

[17]  Masanori Kato,et al.  Abstract 3600: The prominent safety profile of TAS-115, a novel c-Met + VEGFR dual kinase inhibitor can lead to potentiate the efficacy via durable inhibition of angiogenesis , 2011 .

[18]  Lena Claesson-Welsh,et al.  Vascular endothelial growth factors and receptors: anti-angiogenic therapy in the treatment of cancer. , 2011, Molecular aspects of medicine.

[19]  I. Tannock,et al.  Addition of bevacizumab to chemotherapy for treatment of solid tumors: similar results but different conclusions. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  J. Christensen,et al.  HGF/c-Met acts as an alternative angiogenic pathway in sunitinib-resistant tumors. , 2010, Cancer research.

[21]  S. Ogawa,et al.  Gastric cancer cell line Hs746T harbors a splice site mutation of c-Met causing juxtamembrane domain deletion. , 2010, Biochemical and biophysical research communications.

[22]  G. Scagliotti,et al.  Phase III study of carboplatin and paclitaxel alone or with sorafenib in advanced non-small-cell lung cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  R. Kurzrock,et al.  Anti-vascular endothelial growth factor therapies and cardiovascular toxicity: what are the important clinical markers to target? , 2010, The oncologist.

[24]  H. Kalantari,et al.  Predictive factors for severe toxicity of sunitinib in unselected patients with advanced renal cell cancer , 2009, British Journal of Cancer.

[25]  H. Hurwitz,et al.  Vascular Endothelial Growth Factor Receptor 2 Controls Blood Pressure by Regulating Nitric Oxide Synthase Expression , 2009, Hypertension.

[26]  Z. Han,et al.  Cross‐talk between the VEGF‐A and HGF signalling pathways in endothelial cells , 2009, Biology of the cell.

[27]  G. Gores,et al.  Prognostic role of vascular endothelial growth factor in hepatocellular carcinoma: systematic review and meta-analysis , 2009, British Journal of Cancer.

[28]  M. Chen,et al.  Sunitinib‐Induced Cardiotoxicity Is Mediated by Off‐Target Inhibition of AMP‐Activated Protein Kinase , 2009, Clinical and translational science.

[29]  A. Kamath,et al.  High-Throughput Biochemical Kinase Selectivity Assays: Panel Development and Screening Applications , 2009, Journal of biomolecular screening.

[30]  D. V. van Spronsen,et al.  The reverse side of the victory: Flare up of symptoms after discontinuation of sunitinib or sorafenib in renal cell cancer patients. A report of three cases , 2009, Acta oncologica.

[31]  C. Zielinski,et al.  Cardiac toxicity of sunitinib and sorafenib in patients with metastatic renal cell carcinoma. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  David Zurakowski,et al.  Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib , 2007, The Lancet.

[33]  I. Kasman,et al.  MetMAb, the one-armed 5D5 anti-c-Met antibody, inhibits orthotopic pancreatic tumor growth and improves survival. , 2007, Cancer research.

[34]  M. Weiser,et al.  Molecular co-expression of the c-Met oncogene and hepatocyte growth factor in primary colon cancer predicts tumor stage and clinical outcome. , 2007, Cancer letters.

[35]  D. McDonald,et al.  Rapid vascular regrowth in tumors after reversal of VEGF inhibition. , 2006, The Journal of clinical investigation.

[36]  E. Lengyel,et al.  C‐Met overexpression in node‐positive breast cancer identifies patients with poor clinical outcome independent of Her2/neu , 2005, International journal of cancer.

[37]  L. Ellis,et al.  Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[38]  R. Haba,et al.  The tumour–stromal interaction between intratumoral c-Met and stromal hepatocyte growth factor associated with tumour growth and prognosis in non-small-cell lung cancer patients , 2004, British Journal of Cancer.

[39]  W. Birchmeier,et al.  Met, metastasis, motility and more , 2003, Nature Reviews Molecular Cell Biology.

[40]  O. Volpert,et al.  Hepatocyte growth factor/scatter factor mediates angiogenesis through positive VEGF and negative thrombospondin 1 regulation , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[41]  Hui Chen,et al.  Discovery of 5-[5-fluoro-2-oxo-1,2- dihydroindol-(3Z)-ylidenemethyl]-2,4- dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide, a novel tyrosine kinase inhibitor targeting vascular endothelial and platelet-derived growth factor receptor tyrosine kinase. , 2003, Journal of medicinal chemistry.

[42]  E. Rosen,et al.  Scatter factor/hepatocyte growth factor protects against cytotoxic death in human glioblastoma via phosphatidylinositol 3-kinase- and AKT-dependent pathways. , 2000, Cancer research.

[43]  E. Rosen,et al.  Scatter factor protects epithelial and carcinoma cells against apoptosis induced by DNA-damaging agents , 1998, Oncogene.

[44]  K. Maeda,et al.  Combined analysis of p53 and vascular endothelial growth factor expression in colorectal carcinoma for determination of tumor vascularity and liver metastasis , 1997, International journal of cancer.

[45]  O. Vinante,et al.  Prognostic significance of vascular endothelial growth factor protein in node-negative breast carcinoma. , 1997, Journal of the National Cancer Institute.

[46]  T. Sawada,et al.  Prognostic value of vascular endothelial growth factor expression in gastric carcinoma , 1996, Cancer.

[47]  J. Rubin,et al.  Identification of the hepatocyte growth factor receptor as the c-met proto-oncogene product. , 1991, Science.

[48]  W. Travis,et al.  A Report of Three Cases , 1986 .

[49]  W. Gradishar,et al.  A double-blind, randomised, placebo-controlled, phase 2b study evaluating sorafenib in combination with paclitaxel as a first-line therapy in patients with HER2-negative advanced breast cancer. , 2013, European journal of cancer.

[50]  S. Mayor.  MET inhibitors: translating from bench to bedside. , 2011, The Lancet. Oncology.

[51]  K. Grankvist,et al.  Vascular endothelial growth factor as prognostic factor in renal cell carcinoma. , 2000, The Journal of urology.